Universitätsklinikum Leipzig AöR
Welcome,         Profile    Billing    Logout  
 29 Trials 
203 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Platzbecker, Uwe
TUD-APOLLO-064, NCT02688140 / 2015-001151-68: Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia

Active, not recruiting
3
280
Europe
Arsenic trioxide, ATO, Trisenox (R), As2O3, Idarubicin, IDA, Cytarabine, Ara-C, Tretinoin, all-trans retinoic acid, ATRA, Mitoxantrone, MTZ, Mercaptopurine, 6-Mercaptopurine, 6-MP, Methotrexate, MTX
Technische Universität Dresden, Gruppo Italiano Malattie EMatologiche dell'Adulto, Groupe Francophone des Myelodysplasies, HOVON - Dutch Haemato-Oncology Association, Programa para el Tratamiento de Hemopatías Malignas, German Federal Ministry of Education and Research, Teva Pharmaceuticals Europe
Acute Promyelocytic Leukemia
01/25
01/25
NCT04712942: Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat

Completed
2
14
Europe
Pevonedistat, Azacitidine
University of Leipzig, Millennium Pharmaceuticals, Inc.
Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Minimal Residual Disease
01/23
01/23
PEMAZA, NCT03769532 / 2017-004110-25: MRD-guided Treatment in NPM1mut AML Patients

Recruiting
2
28
Europe
Pembrolizumab, PEM, Keytruda®, Azacitidine, AZA, Vidaza®
Technische Universität Dresden, Merck Sharp & Dohme LLC
Acute Myeloid Leukemia
12/25
12/26
IMpress, NCT05583552: Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy

Active, not recruiting
2
46
Europe, RoW
Imetelstat sodium, GRN163L
GCP-Service International West GmbH, Geron Corporation, Universitätsklinikum Leipzig, Saint-Louis Hospital, Paris, France, QIMR Berghofer Medical Research Institute, Australasian Leukaemia and Lymphoma Group, Groupe Francophone des Myelodysplasies, German Myelodysplastic Syndrome Study Group
Myelodysplastic Syndromes, Acute Myeloid Leukemia
02/25
06/26
LUCAS, NCT05178342: Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948

Terminated
2
38
Europe
CA-4948, Emavusertib
University of Leipzig, Curis, Inc.
Myelodysplastic Syndromes, Anemia
07/24
07/24
REMARK_001, NCT06243458: RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

Recruiting
2
41
Europe
RVU120 (SEL120)
GCP-Service International West GmbH, Universitätsklinikum Leipzig, Saint-Louis Hospital, Paris, France, University of Florence, University of Salamanca, Medical University of Warsaw, Ryvu Therapeutics SA, European Myelodysplastic Neoplasms Cooperative Group
Low Risk Myelodysplastic Syndromes
05/26
05/27
MAGROLIC, NCT05829434: Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS

Withdrawn
2
108
NA
Magrolimab, Hu5F9-G4, GS-4721, 7+3, Daunorubicine and Cytarabine, CPX-351, Vyxeos®
Uwe Platzbecker, Gilead Sciences
Acute Myeloid Leukemia, Myelodysplastic Neoplasm
08/28
08/29
APTIVATE, NCT03850574: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
240
Europe, US, RoW
Tuspetinib, HM43239, Venetoclax Oral Tablet, Venetoclax, Azacitidine for Intravenous Infusion, Azacitidine
Aptose Biosciences Inc.
Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome with Excess Blasts-2, Chronic Myelomonocytic Leukemia
11/26
04/27
IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Active, not recruiting
1/2
218
Europe, US
Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto
AbbVie, Jazz Pharmaceuticals
Acute Myeloid Leukemia
04/26
04/26
CA-4948 102, NCT04278768 / 2019-004839-23: Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Recruiting
1/2
366
Europe, US, RoW
Emavusertib, CA-4948, Venetoclax
Curis, Inc., Curis, Inc
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
04/26
04/26
GEMINI II, NCT04718844: A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome

Completed
1
44
Europe, RoW
SLN124, Placebo
Silence Therapeutics plc
Non-transfusion-dependent Thalassemia, Low Risk Myelodysplastic Syndrome, Very-Low Risk Myelodysplastic Syndrome
05/23
05/23
Michalski, Dominik
ESCAPE-NEXT, NCT04462536 / 2020-002360-30: Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis

Completed
3
850
Europe, Canada, US, RoW
Placebo, Nerinetide, NA-1
NoNO Inc., University of Calgary
Stroke, Acute
08/23
08/23
Scheinert, Dierk
NCT03751527: ZENFlex-Registry to Evaluate the Outcome of Bare Metal Stent-assisted Angioplasty

Recruiting
N/A
200
Europe
ZENFLEX peripheral stent system
Zhejiang Zylox Medical Device Co., Ltd.
Atherosclerosis of Femoral Artery
12/22
12/23
NCT04299906: SOLARIS Peripheral PMCF Trial

Active, not recruiting
N/A
70
Europe
Solaris Vascular Stent Graft
Dr. Sabrina Overhagen, FCRE (Foundation for Cardiovascular Research and Education), Scitech Produtos Medicos Ltda
Peripheral Arterial Disease, Iliac Artery Stenosis, Common Femoral Artery Stenosis
11/24
12/24
NCT05132361: SELUTION4SFA Trial

Recruiting
N/A
300
Europe, US, RoW
SELUTION SLR™ 018 DEB, Plain (Uncoated) Balloon Angioplasty (PTA)
MedAlliance, LLC, NAMSA, Cordis Corporation
Peripheral Arterial Disease, Superficial Femoral Artery Stenosis
08/25
12/29
STRIDE II, NCT06747117: A Study of Patients With Lower Extremity Acute Limb Ischemia to Remove Thrombus With the Indigo™ Aspiration System

Not yet recruiting
N/A
300
NA
Indigo Aspiration System
Penumbra Inc.
Lower Extremity Acute Limb Ischemia, LE ALI
06/28
01/29
SOCRATES, NCT04503395: ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR:

Recruiting
N/A
204
Europe
ESAR treatment: Endograft + Heli-FX Endoanchor, FEVAR treatment : Fenestrated endograft
FCRE (Foundation for Cardiovascular Research and Education), Medtronic
Aortic Aneurysm, Abdominal
06/26
06/28
LIMES, NCT04772300: Trial to Assess the Safety and Efficacy of Sirolimus-Coated Balloon vs. Uncoated Standard Angioplasty for the Treatment of Below-the-knee Peripheral Arterial Disease

Recruiting
N/A
230
Europe
Percutaneous Transluminal Angioplasty (PTA) MagicTouch Sirolimus Coated PTA Balloon Catheter, Percutaneous Transluminal Angioplasty (PTA) with non-coated balloon catheter (POBA)
Jena University Hospital, Concept Medical Inc., Vascuscience, CoreLab Black Forest, Center for Clinical Studies, University Hospital Jena
Peripheral Artery Disease
12/27
09/28
Franke, Georg-Nikolaus
IDUNN, NCT04629833 / 2019-001462-15: Treatment of Steroid-Refractory Acute Graft-versus-host Disease with Mesenchymal Stromal Cells Versus Best Available Therapy

Recruiting
3
210
Europe
MC0518, BAT
medac GmbH
Steroid-refractory Acute Graft-versus-host Disease
08/27
08/30
OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive Aspergillosis
09/25
11/26
MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Active, not recruiting
3
249
Europe, Japan, US, RoW
mocravimod
Priothera SAS, Priothera S.A.S.
Adult Acute Myeloid Leukemia
11/25
11/25
MYLOX-1, NCT04679870 / 2020-003087-45: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis

Active, not recruiting
2
21
Europe, US, RoW
GB2064
Galecto Biotech AB, OPIS s.r.l
Myelofibrosis
12/23
06/26
TAK-620-5010, NCT06615921: A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection

Recruiting
N/A
150
Europe, RoW
No Intervention
Takeda
Cytomegalovirus (CMV)
04/25
04/25
Schmidt, Andrej
NCT04799769: Safety and Performance Study of Large Hole Vascular Closure Device - FRONTIER V Study

Recruiting
N/A
90
Europe
Percutaneous arterial closure device
Vivasure Medical Limited
Percutaneous Arteriotomy Closure
01/23
03/23
HEAL, NCT04110327: An All-Comers Observational Study of the MicroStent™ Peripheral Vascular Stent System in Subjects with Peripheral Arterial Disease

Recruiting
N/A
300
Europe
MicroStent
Micro Medical Solution, Inc.
Peripheral Arterial Disease, Critical Lower Limb Ischemia
12/26
12/28
NCT05406622: MOTIV BTK Randomized Controlled Trial

Recruiting
N/A
292
Europe, US
MOTIV Sirolimus-Eluting Bioresorbable Scaffold, Percutaneous Transluminal Angioplasty (PTA) Device
REVA Medical, Inc.
Critical Limb Ischemia
09/25
03/29
PRAEVA-2-LP, NCT05920317: Comparison of a Full Automatic Software With Standard Methods of Vessels Analysis

Recruiting
N/A
50
Europe
Nurea, Universitätsklinikum Leipzig
Abdominal Aortic Aneurysm
11/23
12/23
NCT05653336: PerQseal® Clinical Study

Active, not recruiting
N/A
149
Europe, US
PerQseal® Closure Device System
Vivasure Medical Limited
Percutaneous Large Hole Vascular Closure
12/24
06/25
NCT03982940: BGP+ Stent as Bridging Stent in BEVAR

Active, not recruiting
N/A
118
Europe
BGP+ Stent Graft System as bridging stent
Dr. Sabrina Overhagen, Bentley InnoMed GmbH
Thoracoabdominal Aortic Aneurysm, Without Mention of Rupture
05/24
07/25
ADVANCE, NCT05378347: Endurant Stent Graft System vs Excluder Endoprothesis: Trial

Recruiting
N/A
550
Europe, Japan, US, RoW
Medtronic Endurant II or Endurant IIs Stent Graft System, Gore Excluder or Gore/ Excluder Conformable AAA Endoprosthesis
Medtronic Cardiovascular
Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder), Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)
05/27
05/31
DEFIANCE, NCT05701917: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis

Recruiting
N/A
300
Europe, US
ClotTriever System, Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.
Inari Medical
Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
06/25
10/25
NCT04393389: Acotec DCB Post Market Clinical Follow-up

Recruiting
N/A
3000
Europe
AcoArt Orchid (0.035"), AcoArt Tulip (0.018") and AcoArt Litos (0.014") percutaneous transluminal angioplasty (PTA) paclitaxel drug coated balloon catheter manufactured by Acotec Scientific Co., Ltd.
Acotec Scientific Co., Ltd
Peripheral Artery Disease
12/25
03/27
ILICO, NCT05192616: Safety and Effectiveness Evaluation of iCover Covered Stent for the Treatment of the Aorto-iliac Occlusive Disease

Not yet recruiting
N/A
214
Europe
Covered stent implantation
iVascular S.L.U.
Angioplasty, Peripheral Arterial Disease, Iliac Artery Disease, Covered Stent, Aorto-Iliac Atherosclerosis
05/24
05/25
Hoffmeister, Albrecht
RAMTAS, NCT03520946 / 2017-004162-99: RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

Completed
3
430
Europe
Ramucirumab, TAS 102
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Eli Lilly and Company, Trium Analysis Online GmbH
Colorectal Cancer
07/24
07/24
Contact, Site Public
NCT04985682 / 2022-004149-11: A Study of ADVATE in People With Hemophilia A in India

Completed
4
50
RoW
ADVATE
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Hemophilia A
02/23
02/23
SWITCH, NCT04718779: A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy

Completed
4
4
US
Digital Engagement Application (GD App), No Intervention
Takeda
Gaucher Disease
02/23
02/23
COMPASS-CD, NCT04809363: A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

Active, not recruiting
4
200
US
CDPATH™, PROSPECT, Blood Draw
Takeda
Crohn's Disease
10/25
06/26
NCT05341115 / 2022-002471-11: A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty

Recruiting
4
80
RoW
Leuprorelin Acetate Depot 3M, Leuprolide acetate Depot 3M
Takeda, Takeda
Central Precocious Puberty
05/25
05/25
TAK-665-4001, NCT05058391 / 2022-004193-39: A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India

Completed
4
5
RoW
Elaprase, Idursulfase
Takeda, Takeda Biopharmaceuticals India Pvt. Ltd.
Hunter Syndrome
04/24
04/24
NCT05442554: A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma

Completed
4
10
RoW
Brentuximab vedotin, SGN-35
Takeda
T-Cell Lymphoma
08/24
08/24
NCT05067868: A Study of Replagal in Children and Adults With Fabry Disease in India

Active, not recruiting
4
5
RoW
Replagal
Shire
Fabry Disease
10/26
11/26
TAK-113-4002, NCT06562543: A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

Recruiting
4
78
US
Fruquintinib, Fruzaqla™
Takeda
Colorectal Cancer
02/28
02/28
NCT04085172 / 2018-000821-29: A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

Active, not recruiting
4
288
Europe, US
Guanfacine hydrochloride (TAK-503), Intuniv, SPD503, Atomoxetine hydrochloride, Placebo
Shire, Takeda Development Center Americas, Inc.
Attention Deficit Hyperactivity Disorder
06/27
06/27
ASPIRE, NCT04118088 / 2017-002491-10: A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula

Active, not recruiting
4
50
Europe, RoW
Darvadstrocel, Alofisel, Cx601
Takeda, Takeda Development Center Americas, Inc.
Crohn's Disease, Complex Perianal Fistula
03/26
03/26
NCT05494593: A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)

Recruiting
4
5
US
ELAPRASE, Idursulfase, Rituximab, Methotrexate, Intravenous Immunoglobulin (IVIG)
Takeda, Takeda Development Center Americas, Inc.
Mucopolysaccharidosis (MPS), Hunter Syndrome
07/28
07/28
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Recruiting
4
150
Canada, US
Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara
Takeda
Crohn's Disease
06/27
06/27
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Recruiting
4
65
Canada, US
Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550
Takeda
Ulcerative Colitis
07/27
07/27
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Checkmark Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Checkmark Initiation of new trial in Ph+ ALL
Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL
Active, not recruiting
3
245
Europe, Canada, Japan, US, RoW
Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Takeda
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
08/22
07/27
NCT04840667 / 2018-004689-32: A Study of Replagal in Treatment-naïve Adults With Fabry Disease

Terminated
3
17
Europe, Canada
REPLAGAL, SHP675
Shire
Fabry Disease
12/22
12/22
NCT04444895 / 2019-004823-20: A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Completed
3
73
Europe, Canada, Japan, US
Lanadelumab, DX-2930, SHP643, TAK-743
Shire, Takeda Development Center Americas, Inc.
Angioedema
05/23
05/23
NCT03393975 / 2017-000858-18: A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

Completed
3
51
Europe, Japan, US
BAX930, rADAMTS13, SHP-655, TAK-755, recombinant ADAMTS13, BAX 930, Standard of care
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Thrombotic Thrombocytopenic Purpura (TTP)
12/23
05/24
NCT03879135 / 2018-003453-16: A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

Active, not recruiting
3
38
Europe, US, RoW
rVWF, Vonvendi, Vonicog alfa, rFVIII, Octocog alfa, ADVATE
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease (VWD)
03/25
03/25
SKYWAY, NCT04938427 / 2021-002481-40: A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

Completed
3
270
Europe, Canada, Japan, US, RoW
Placebo, Soticlestat, TAK-935
Takeda
Lennox Gastaut Syndrome (LGS)
01/24
01/24
NCT06165341: Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

Recruiting
3
50
Europe, Canada, US
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo
Takeda
Alpha1-Antitrypsin Deficiency
08/28
08/28
NCT02932618 / 2016-001477-33: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Recruiting
3
34
Europe, US, RoW
von Willebrand factor (Recombinant), VONVENDI, rVWF, BAX111, BAX 111, Antihemophilic Factor (Recombinant), ADVATE, Recombinant Factor VIII, rFVIII
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease
01/25
01/25
SKYLINE, NCT04940624 / 2021-002480-22: A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

Completed
3
144
Europe, Canada, Japan, US, RoW
Soticlestat, TAK-935, Placebo
Takeda
Dravet Syndrome (DS)
04/24
04/24
TAK-935-3004, NCT06422377: A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine

Terminated
3
1
Europe
Soticlestat, TAK-935
Takeda
Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)
08/24
08/24
NCT04974749 / 2022-004246-35: A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease

Completed
3
20
RoW
REPLAGAL, Agalsidase Alfa, TAK-675
Takeda, Takeda Development Center Americas, Inc
Fabry Disease
01/24
01/24
NCT05460325 / 2023-001105-31: A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

Completed
3
20
RoW
Lanadelumab, SHP643, TAKHZYRO, TAK-743, DX-2930, Lanadelumab Injection
Takeda, Takeda
Hereditary Angioedema (HAE)
11/23
11/23
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
Vedolizumab-3041, NCT06443502: A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis

Recruiting
3
30
Europe, RoW
Vedolizumab, Entyvio, MLN0002, Kynteles, Concomitant Antibiotic Therapy
Takeda
Pouchitis
12/29
12/29
NCT06060067 / 2023-000134-15: A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India

Active, not recruiting
3
480
RoW
TDV, TAK-003, Placebo
Takeda, Takeda
Healthy Volunteers
05/25
05/25
NCT04779320 / 2020-004301-31: A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Recruiting
3
120
Europe, Canada, Japan, US, RoW
Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002
Takeda, Takeda Development Center Americas, Inc.
Crohn's Disease (CD)
11/24
11/24
NCT05529992 / 2022-002323-35: A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease

Completed
3
20
RoW
Velaglucerase Alfa, VPRIV
Takeda, Takeda
Gaucher Disease
08/24
08/24
NCT05707351: A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A

Completed
3
37
RoW
Adynovate, Antihemophilic Factor (recombinant) PEGylated, Rurioctocog Alfa Pegol
Takeda
Hemophilia A
09/24
09/24
VICTRIVA, NCT06227910: A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

Recruiting
3
396
Canada, US
Vedolizumab, Entyvio, MLN0002, KYNTELES, Upadacitinib, Rinvoq, Placebo
Takeda
Crohn's Disease
06/27
08/28
NCT06439342: A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections

Not yet recruiting
3
20
RoW
Maribavir, TAK-620
Takeda
Cytomegalovirus (CMV)
02/27
02/27
SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting
3
700
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806
SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
03/25
03/28
NCT04701411 / 2020-003193-48: A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and Teenagers With Crohn's Disease

Recruiting
3
20
Europe, Japan, RoW
Darvadstrocel, Cx601
Takeda, Takeda Development Center Americas, Inc.
Crohn's Disease, Complex Perianal Fistula
06/25
12/25
ACTION-1, NCT05477576 / 2022-000507-12: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting
3
288
Europe, Canada, US, RoW
RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide
RayzeBio, Inc., RayzeBio, Inc.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
12/25
07/28
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Active, not recruiting
3
1108
Europe, Canada, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
12/24
11/25
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Active, not recruiting
3
693
Europe, Canada, Japan, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
08/25
04/26
MLN0002-3024, NCT04779307 / 2020-004300-34: A Study of Vedolizumab in Children and Teenagers with Moderate to Severe Ulcerative Colitis (UC)

Active, not recruiting
3
121
Europe, Canada, Japan, US, RoW
Vedolizumab, MLN0002, ENTYVIO, KYNTELES
Takeda, Takeda Development Center Americas, Inc.
Colitis, Ulcerative
08/25
08/25
NCT04759833 / 2022-003221-22: A Study of Prucalopride For Functional Constipation in Children and Teenagers

Terminated
3
175
US
Prucalopride, TAK-555, Prucalopride succinate, Placebo
Takeda, Takeda Development Center Americas, Inc.
Constipation
11/23
11/23
NCT05156983 / 2021-004138-12: A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

Recruiting
3
328
Europe, Canada, US
TAK-330, SOC 4F-PCC
Takeda, Takeda Development Center Americas, Inc.
Coagulation Disorder
04/28
04/28
ENDYMION 2, NCT05163314 / 2021-002482-17: A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

Recruiting
3
400
Europe, Canada, Japan, US, RoW
Soticlestat, TAK-935
Takeda
Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS)
05/26
05/26
NCT04683003: A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Recruiting
3
77
Europe, Japan, US, RoW
TAK-755, rADAMTS13; recombinant ADAMTS13; SHP-655; BAX 930
Takeda, Takeda Development Center Americas, Inc., Shire
Thrombotic Thrombocytopenic Purpura (TTP)
03/27
03/27
TAK-620-2004, NCT05319353 / 2021-004279-15: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

Active, not recruiting
3
80
Europe, Japan, US, RoW
Maribavir, TAK-620
Takeda, Takeda Development Center Americas, Inc.
Cytomegalovirus (CMV)
01/27
01/27
NCT04969731: Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

Recruiting
3
408
RoW
Immuncell-LC, Autologous activated T lymphocyte, Gemcitabine
GC Cell Corporation
Pancreatic Ductal Adenocarcinoma
12/26
06/27
PACES, NCT01349881: S0820, Adenoma and Second Primary Prevention Trial

Active, not recruiting
3
354
US
Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac
SWOG Cancer Research Network, National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc.
Colorectal Neoplasms
02/27
02/32
NCT05582993 / 2020-003304-13: A Study of Recombinant Von Willebrand Factor (rVWF) (TAK-577) in Children With Severe Von Willebrand Disease (vWD)

Recruiting
3
24
Europe, US
Recombinant von Willebrand Factor (rVWF), TAK-577, Vonicog Alfa, ADVATE, Recombinant Factor VIII (rFVIII), Octocog Alfa
Takeda, Takeda Development Center Americas, Inc.
Von Willebrand Disease (VWD)
04/30
04/30
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Recruiting
3
160
Europe, Canada, US, RoW
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride
Takeda, Takeda Development Center Americas, Inc.
Alpha1-Antitrypsin Deficiency
03/27
03/29
TAK-881-3002, NCT06076642: A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

Recruiting
3
39
US
TAK-881, Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20)., SC Investigational Needle Sets
Takeda, Takeda Development Center Americas, Inc., Baxalta Innovations GmbH, now part of Takeda
Primary Immunodeficiency Diseases (PID)
01/29
01/29
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
NCT03221036: Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis

Recruiting
3
402
RoW
Vedolizumab IV, Placebo
Takeda
Moderately to Severely Active Ulcerative Colitis
05/28
07/28
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
NCT05837897: A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease

Recruiting
3
408
RoW
Vedolizumab IV, Placebo
Takeda
Crohn's Disease
03/30
05/31
NCT05442567 / 2021-000630-34: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Recruiting
3
240
Europe, Canada, Japan, US, RoW
Vedolizumab IV, MLN0002, ENTYVIO, KYNTELES, No Intervention
Takeda, Takeda Development Center Americas, Inc.
Ulcerative Colitis, Crohn's Disease
08/31
08/31
NCT05755035: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Recruiting
2/3
75
Europe, US, RoW
TAK-881, Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20)., HYQVIA, Immune Globulin Infusion (Human), 10% Solution with rHuPH20.
Takeda, Takeda Development Center Americas, Inc.
Primary Immunodeficiency Diseases (PID)
02/26
09/26
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
NCT06031259: Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment

Recruiting
2/3
8
Europe, Canada
Idursulfase-IT, Elaprase
Takeda
Hunter Syndrome
01/34
06/34
NCT05000216: COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Completed
2
257
US
Moderna mRNA-1273, mRNA-1273 vaccine (Moderna), Moderna COVID-19 Vaccine, SARS-CoV-2 RNA vaccine, COVID-19 vaccine, BNT162b2, mRNA-1273 vaccine (Pfizer/BioNTech), Pfizer-BioNTech COVID-19 vaccine, Ad26.COV2.S, Janssen COVID-19 Vaccine, JNJ-78436735, Continue IS (MMF or MPA), immunosuppressive medication, mycophenolate mofetil, MMF, CellCept®, mycophenolic acid, MPA, Continue IS (MTX), methotrexate, MTX, Continue IS (B cell depletion therapy), mAbs targeting CD19 or CD20, anti-BAFF mAb, Monovalent [B.1.351] CoV2 preS dTM-AS03, Sanofi-GSK COVID-19 Vaccine, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, mRNA-1273 vaccine (Moderna), Bivalent, Moderna COVID-19 Vaccine, Bivalent, SARS-CoV-2 RNA vaccine, Bivalent, COVID-19 vaccine, Bivalent, BNT162b2, Bivalent, mRNA-1273 vaccine (Pfizer/BioNTech), Bivalent, Pfizer-BioNTech COVID-19 vaccine, Bivalent
National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc.
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
06/23
03/24
NCT04530123: Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

Recruiting
2
90
Canada, US, RoW
Placebo, TAK-101, Gluten
Takeda
Celiac Disease
10/25
10/25
ALTITUDE-AD, NCT06335173: A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants with Early Alzheimer's Disease

Active, not recruiting
2
540
Europe, Canada, US
sabirnetug, Placebo
Acumen Pharmaceuticals
Alzheimer Disease
10/26
10/26
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
NCT05814016: A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery

Terminated
2
41
US
Danavorexton, TAK-925, Placebo
Takeda
Sleep Apnea
09/24
09/24
NCT05469802: A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults

Withdrawn
2
78
US
Purified Inactivated Zika Virus Vaccine (PIZV), TAK-426, Placebo
Takeda
Healthy Volunteers
07/24
07/24
NCT04278924 / 2019-004103-12: A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

Completed
2
41
Europe, Japan, US, RoW
Placebo, TAK-079
Takeda
Primary Immune Thrombocytopenia
04/24
04/24
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
01/26
01/28
 

Download Options